BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20471184)

  • 21. Increased standardized uptake value in the primary lesion predicts nodal or distant metastases at presentation in lung cancer.
    Sachs S; Bilfinger TV; Komaroff E; Franceschi D
    Clin Lung Cancer; 2005 Mar; 6(5):310-3. PubMed ID: 15845183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study.
    Yu J; Li X; Xing L; Mu D; Fu Z; Sun X; Sun X; Yang G; Zhang B; Sun X; Ling CC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1468-74. PubMed ID: 19464822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use.
    Weber WA; Petersen V; Schmidt B; Tyndale-Hines L; Link T; Peschel C; Schwaiger M
    J Clin Oncol; 2003 Jul; 21(14):2651-7. PubMed ID: 12860940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy.
    Nawara C; Rendl G; Wurstbauer K; Lackner B; Rettenbacher L; Datz L; Studnicka M; Sedlmayer F; Pirich C
    Q J Nucl Med Mol Imaging; 2012 Apr; 56(2):191-201. PubMed ID: 22402822
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
    Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):151-9. PubMed ID: 15999056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Point: Clinical stage IA non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non-small cell lung cancer: the problem of understaging.
    Stiles BM; Servais EL; Lee PC; Port JL; Paul S; Altorki NK
    J Thorac Cardiovasc Surg; 2009 Jan; 137(1):13-9. PubMed ID: 19154893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fractionated stereotactic body radiation therapy in the treatment of primary, recurrent, and metastatic lung tumors: the role of positron emission tomography/computed tomography-based treatment planning.
    Coon D; Gokhale AS; Burton SA; Heron DE; Ozhasoglu C; Christie N
    Clin Lung Cancer; 2008 Jul; 9(4):217-21. PubMed ID: 18650169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impact of PET/CT on precise radiotherapy planning for non-small cell lung cancer].
    Gong HY; Yu JM; Fu Z; Li BS; Li JB; Liu TH
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):54-7. PubMed ID: 16737623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endobronchial/Endoesophageal Ultrasound (EBUS/EUS) Guided Fine Needle Aspiration (FNA) and 18F-FDG PET/CT Scanning in Restaging of Locally Advanced Non-small Cell Lung Cancer (NSCLC) Treated with Chemo-radiotherapy: A Mono-institutional Pilot Experience.
    Genestreti G; Burgio MA; Matteucci F; Piciucchi S; Scarpi E; Monti M; Bucchi L; Parisi E; Crociani L; Gurioli C; Poletti V; Gavelli G
    Technol Cancer Res Treat; 2015 Dec; 14(6):721-7. PubMed ID: 24945370
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic value of (18)F-fluorodeoxyglucose uptake in patients with non-small cell lung cancer treated by concurrent chemoradiotherapy].
    Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
    Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):603-6. PubMed ID: 21122413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer.
    Poettgen C; Theegarten D; Eberhardt W; Levegruen S; Gauler T; Krbek T; Stamatis G; Teschler H; Kuehl H; Bockisch A; Stuschke M
    Oncology; 2007; 73(5-6):316-23. PubMed ID: 18497503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy.
    Lazanyi KS; Abramyuk A; Wolf G; Tokalov S; Zöphel K; Appold S; Herrmann T; Baumann M; Abolmaali N
    Lung Cancer; 2010 Dec; 70(3):280-5. PubMed ID: 20371133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
    van Loon J; Grutters J; Wanders R; Boersma L; Oellers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Fatah SA; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2009 Mar; 45(4):588-95. PubMed ID: 19046631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Limited prognostic value of dual time point F-18 FDG PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC).
    Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK
    Radiother Oncol; 2011 Jan; 98(1):105-8. PubMed ID: 21159395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria?
    Casiraghi M; Travaini LL; Maisonneuve P; Tessitore A; Brambilla D; Agoglia BG; Guarize J; Spaggiari L
    Eur J Cardiothorac Surg; 2011 Apr; 39(4):e38-43. PubMed ID: 21242094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
    Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
    Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
    Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy.
    Bruzzi JF; Truong M; Zinner R; Erasmus JJ; Sabloff B; Munden R
    J Thorac Oncol; 2006 Jun; 1(5):425-9. PubMed ID: 17409894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.